111 related articles for article (PubMed ID: 8297902)
1. Tumor cells expressing major histocompatibility complex class II and B7 activation molecules stimulate potent tumor-specific immunity.
Baskar S; Nabavi N; Glimcher LH; Ostrand-Rosenberg S
J Immunother Emphasis Tumor Immunol; 1993 Oct; 14(3):209-15. PubMed ID: 8297902
[TBL] [Abstract][Full Text] [Related]
2. Expression of MHC Class II and B7-1 and B7-2 costimulatory molecules accompanies tumor rejection and reduces the metastatic potential of tumor cells.
Ostrand-Rosenberg S; Baskar S; Patterson N; Clements VK
Tissue Antigens; 1996 May; 47(5):414-21. PubMed ID: 8795142
[TBL] [Abstract][Full Text] [Related]
3. Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules.
Baskar S; Ostrand-Rosenberg S; Nabavi N; Nadler LM; Freeman GJ; Glimcher LH
Proc Natl Acad Sci U S A; 1993 Jun; 90(12):5687-90. PubMed ID: 7685909
[TBL] [Abstract][Full Text] [Related]
4. Rejection of MHC class II-transfected tumor cells requires induction of tumor-encoded B7-1 and/or B7-2 costimulatory molecules.
Baskar S; Clements VK; Glimcher LH; Nabavi N; Ostrand-Rosenberg S
J Immunol; 1996 May; 156(10):3821-7. PubMed ID: 8621919
[TBL] [Abstract][Full Text] [Related]
5. Tumor-specific immunity can be enhanced by transfection of tumor cells with syngeneic MHC-class-II genes or allogeneic MHC-class-I genes.
Ostrand-Rosenberg S; Roby C; Clements VK; Cole GA
Int J Cancer Suppl; 1991; 6():61-8. PubMed ID: 1906055
[TBL] [Abstract][Full Text] [Related]
6. MHC class II-transfected tumor cells induce long-term tumor-specific immunity in autologous mice.
Baskar S; Azarenko V; Garcia Marshall E; Hughes E; Ostrand-Rosenberg S
Cell Immunol; 1994 Apr; 155(1):123-33. PubMed ID: 8168141
[TBL] [Abstract][Full Text] [Related]
7. Abrogation of tumorigenicity by MHC class II antigen expression requires the cytoplasmic domain of the class II molecule.
Ostrand-Rosenberg S; Roby CA; Clements VK
J Immunol; 1991 Oct; 147(7):2419-22. PubMed ID: 1918972
[TBL] [Abstract][Full Text] [Related]
8. Rejection of mouse sarcoma cells after transfection of MHC class II genes.
Ostrand-Rosenberg S; Thakur A; Clements V
J Immunol; 1990 May; 144(10):4068-71. PubMed ID: 2332639
[TBL] [Abstract][Full Text] [Related]
9. Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice.
Baskar S; Glimcher L; Nabavi N; Jones RT; Ostrand-Rosenberg S
J Exp Med; 1995 Feb; 181(2):619-29. PubMed ID: 7836917
[TBL] [Abstract][Full Text] [Related]
10. Invariant chain alters the malignant phenotype of MHC class II+ tumor cells.
Clements VK; Baskar S; Armstrong TD; Ostrand-Rosenberg S
J Immunol; 1992 Oct; 149(7):2391-6. PubMed ID: 1527384
[TBL] [Abstract][Full Text] [Related]
11. Induction and maintenance of T-cell response to a nonimmunogenic murine mesothelioma cell line requires expression of B7-1 and the capacity to upregulate class II major histocompatibility complex expression.
Leong C; Marley J; Loh S; Robinson B; Garlepp M
Cancer Gene Ther; 1996; 3(5):321-30. PubMed ID: 8894251
[TBL] [Abstract][Full Text] [Related]
12. Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity.
Armstrong TD; Clements VK; Martin BK; Ting JP; Ostrand-Rosenberg S
Proc Natl Acad Sci U S A; 1997 Jun; 94(13):6886-91. PubMed ID: 9192661
[TBL] [Abstract][Full Text] [Related]
13. Transfection of major histocompatibility complex class I and class II genes causes tumour rejection.
Ostrand-Rosenberg S; Clements VK; Thakur A; Cole GA
J Immunogenet; 1989; 16(4-5):343-9. PubMed ID: 2639907
[TBL] [Abstract][Full Text] [Related]
14. GM-CSF and B7-1 (CD80) co-stimulatory signals co-operate in the induction of effective anti-tumor immunity in syngeneic mice.
Sumimoto H; Tani K; Nakazaki Y; Tanabe T; Hibino H; Hamada H; Azuma M; Asano S
Int J Cancer; 1997 Nov; 73(4):556-61. PubMed ID: 9389572
[TBL] [Abstract][Full Text] [Related]
15. Invariant chain and the MHC class II cytoplasmic domains regulate localization of MHC class II molecules to lipid rafts in tumor cell-based vaccines.
Dolan BP; Phelan TP; Ilkovitch D; Qi L; Wade WF; Laufer TM; Ostrand-Rosenberg S
J Immunol; 2004 Jan; 172(2):907-14. PubMed ID: 14707062
[TBL] [Abstract][Full Text] [Related]
16. Antigen-specific regression of established tumors induced by active immunization with irradiated IL-12- but not B7-1-transfected tumor cells.
Fallarino F; Ashikari A; Boon T; Gajewski TF
Int Immunol; 1997 Sep; 9(9):1259-69. PubMed ID: 9310829
[TBL] [Abstract][Full Text] [Related]
17. Transgenic mice expressing MHC class II molecules with truncated A beta cytoplasmic domains reveal signaling-independent defects in antigen presentation.
Smiley ST; Laufer TM; Lo D; Glimcher LH; Grusby MJ
Int Immunol; 1995 Apr; 7(4):665-77. PubMed ID: 7547694
[TBL] [Abstract][Full Text] [Related]
18. MHC class II-transfected tumor cells directly present antigen to tumor-specific CD4+ T lymphocytes.
Armstrong TD; Clements VK; Ostrand-Rosenberg S
J Immunol; 1998 Jan; 160(2):661-6. PubMed ID: 9551900
[TBL] [Abstract][Full Text] [Related]
19. Manipulation of T cell response to tumors by targeting on costimulatory pathway.
Chen L
Leukemia; 1997 Apr; 11 Suppl 3():567-9. PubMed ID: 9209456
[TBL] [Abstract][Full Text] [Related]
20. Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules.
Yang G; Hellström KE; Hellström I; Chen L
J Immunol; 1995 Mar; 154(6):2794-800. PubMed ID: 7533183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
